Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
2(40%)
Results Posted
300%(3 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
3
60%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

terminated240%
completed120%
recruiting120%
active_not_recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
terminatedphase_2

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

NCT05846659
recruitingphase_2

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

NCT06601296
terminatedphase_2

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

NCT05846646
completedphase_1

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

NCT04020185
active_not_recruitingphase_1

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

NCT06026254

Clinical Trials (5)

Showing 5 of 5 trials
NCT05846659Phase 2

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Terminated
NCT06601296Phase 2

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

Recruiting
NCT05846646Phase 2

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Terminated
NCT04020185Phase 1

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Completed
NCT06026254Phase 1

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

Active Not Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5